Haploidentical (HID)-allogeneic hematopoietic cell transplantation (allo-HCT) was just as effective as matched donor (MD)-HCT in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) who received tyrosine kinase inhibitors (TKIs), according to a systematic review and meta-analysis. The results were presented during the 2021 ASCO Annual Meeting. ...
ASCO 2021 Annual Meeting Conference Coverage
Advertisement
Ph-like ALL is a high-risk subgroup with increased prevalence in younger adults.
A retrospective study assessed how advanced care planning affected end-of-life outcomes in patients who underwent allo-HCT.
A study presented during ASCO 2021 reviewed a program to streamline discussions surrounding fertility preservation options.
The results were presented during the 2021 ASCO Annual Meeting.
Data were collected on 541 patients with incurable solid tumor or lymphoma considering any line of cancer treatment.
Satisfaction with telehealth is on the rise. However, differences persist by demographic.
The lives of patients who undergo hematopoietic stem cell transplantation (HSCT) change in several ways.
Final analysis included 138 patients who underwent lung metastasectomy.
Advertisement
